Multiple studies show that specific hormonal therapies reduce the locoregional recurrences of luminal A/B or HER2 enriched breast cancers [87,88,89], but TNBC locoregional recurrences remain unchanged due to the lack of hormone receptors. This evidence concerns the gene ERBB2 and breast carcinoma.